Williamson Stephen

Williamson Stephen, serving as Senior VP and CFO across two companies, has filed 41 Form 4 transactions that collectively show a pronounced sell-side bias. Over the tracked period, his open-market sales totaled $24.5 million, while he recorded zero open-market purchases. The activity is concentrated in Honeywell (HON) and Thermo Fisher Scientific (TMO), with the bulk of the selling occurring through automatic, non-discretionary events rather than discretionary trades. The recent filings reveal a pattern dominated by compensation mechanics rather than active portfolio management. In February 2026, Williamson had four separate "F" code transactions at TMO—shares withheld to cover tax obligations—totaling approximately $960,711. A similar cluster appeared in August 2025, with eight "F" transactions at TMO valued at roughly $767,200 combined. These are automatic withholdings tied to equity vesting, not market-timed sales. The only "M" code (option exercise) appeared on April 15, 2026, at HON for $144,331, which is a mechanical conversion rather than a conviction trade. The compensation component is evident throughout: multiple "A" code grants at HON in January and October 2025, and again in January 2026, each valued between $33,750 and $60,000, alongside a February 2025 TMO award. A November 2025 gift at TMO (code "G") carried no monetary value. The absence of any "P" code purchases—the only transaction type signaling conviction—combined with the steady stream of tax-withholding sales and option exercises, indicates Williamson's filings reflect routine equity compensation administration rather than an active directional bet on either stock. His total acquired value of $254,998 is dwarfed by the $24.5 million in sales, but nearly all of that selling is mechanical, tied to vesting schedules and tax obligations.